Makers Laboratories Ltd.

Regd. Office : 54-D, Kandivali Indl. Estate, Kandivali (West), Mumbai - 400 067.
CIN: L24230MH1984PLC033389, website: www.makerslabs.com, e-mail: makers@makerslabs.com

THRU ONLINE FILING

August 7, 2026

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023.

Dear Sir,

Re : **Outcome of Board Meeting**

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith our Unaudited Standalone and Consolidated Financial Results along with the limited review report of the Company's Auditors thereon for the 1st Quarter ended 30th June, 2026, which was taken on record at the Meeting of the Board of Directors of the Company held today at Kandivli, Mumbai.

2. The Board also noted that the term of appointment of Mr. Saahil Parikh (DIN 00400079) as the Whole-time Director/CEO of the Company is coming to an end on 10th August, 2026 and that Mr. Saahil Parikh has informed the Board that he does not wish to be re-appointed as the Whole-time Director/CEO of the Company, due to personal and professional reasons. He has confirmed that there are no other material reasons for this decision.

   However, since he has agreed to continue as the Non-Executive Director, the Board has appointed him as the Non-Executive, Non-Independent Director of the Company w.e.f 11th August, 2026, subject to the approval of the shareholders of the Company.

   Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 of the change in the Directorship of Mr. Saahil Parikh:

Name : Mr. Saahil Parikh (DIN 00400079)		
1.	Reason for Change	Appointed as the Non-Executive, Non-Independent Director w.e.f. 11th August, 2026 upon completion of his term of appointment as the Whole-time Director/CEO of the Company on 10th August, 2026, subject to the approval of the Shareholders.
2.	Date of appointment & term of appointment	Liable to retire by rotation as a Director.

3.	Brief Profile (in case of appointment)	Mr. Saahil Parikh aged 51 years has done his graduation in Bio-Chemistry from Gujarat University. He has also done Diploma in Management Studies from Ahmedabad Management Association. He has about 25 years of experience in the pharma industry in the field of pharma production, quality control, pharma projects and general management.
4.	Disclosure of relationships between directors	Not related to any Director or Key Managerial Personnel of the Company. He is not debarred from holding the office of the Directorship by virtue of order passed by SEBI or by any other competent authority.

3. With this change in this Directorship, the revised composition of the Board of Directors of the Company w.e.f. 11th August, 2026 shall be as under :

Mr. R. K. P. Verma	Chairman, Independent Director
Ms. Dipti Shah	Independent Director
Mr. Vishal Jain	Independent Director
Mr. Prashant Godha	Non-Executive, Non-Independent Director
Mr. Saahil Parikh	Non-Executive, Non-Independent Director
Mr. Nilesh Jain	Executive, Whole-time Director

We confirm that none of the Directors of the Company are debarred from holding the office of the Directorship by virtue of order passed by SEBI or by any other competent authority.

4. Due to the above changes in the Directorship, the following Committees of the Board is re-constituted as under :

Stakeholders Relationship Committee	Mr. R. K. P. Verma	Chairman of the Committee / Independent Director
	Mr. Vishal Jain	Independent Director
	Mr. Saahil Parikh	Director
Risk Management Committee	Mr. Saahil Parikh	Director
	Mr. Nilesh Jain	Executive, Whole-time Director
	Mr. Sandeep Kadam	Sr. Manager (Accounts) / CFO

Kindly note the meeting started at 11.00 a.m. and concluded at 11.55 a.m.

Thanking you.

Yours faithfully
For Makers Laboratories Limited

PIYUSH AJMERA

Digitally signed by PIYUSH AJMERA
DN: c=IN, postalCode=400097, st=MAHARASHTRA, street=1702, ALTA MONTE TOWER -A ,CTS NO -821, OFF WESTERN EXPRESS HIGHWAY ,MUMBAI SUBURBAN,MALAD EAST ,400097, l=MUMBAI SUBURBAN, o=Personal,
serialNumber=ddad07b704db31121cbbadf262f90f81a356aa1a2e714ad06d4648884cbeb8ef,
pseudonym=684760414dd847958b61135ba7aa17f7,
2.5.4.20=668e1f52087653926bc09a8e04e54da83e9d831004b76b71ed4ad8dd35d5fa8e,
email=PIYUSHAJMERA90@GMAIL.COM, cn=PIYUSH AJMERA
Date: 2026.08.07 11:58:36 +05'30'

Piyush Ajmera, Company Secretary (ACS 58712)

Makers Laboratories Limited

Regd. Office : 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24230MH1984PLC033389

Tel:+91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(All Figures are Rupees in Lacs unless otherwise stated)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	1,018.75	1,127.46	1,372.68	5,034.73
II	Other Income	7.15	2.46	3.90	59.28
III	**Total Income (I + II)**	**1,025.90**	**1,129.92**	**1,376.58**	**5,094.01**
IV	**Expenses:**				
	a) Cost of materials consumed	141.84	99.60	161.22	546.49
	b) Purchases of stock-in-trade	546.96	571.84	702.96	2220.36
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(241.24)	(72.14)	(146.47)	(165.00)
	d) Employee benefit expenses	246.16	226.97	237.19	968.92
	e) Finance Cost	13.59	12.26	10.20	53.07
	f) Depreciation and amortisation expense	69.41	69.20	69.89	280.40
	g) Other expenses	374.90	338.31	371.54	1390.90
	Total Expenses (IV)	**1,151.62**	**1,246.04**	**1,406.53**	**5,295.14**
V	**Profit/ (Loss) Before exceptional items and Tax (III - IV)**	**(125.72)**	**(116.12)**	**(29.95)**	**(201.13)**
VI	Exceptional Items income/ (expenses)	-	-	-	-
VII	**Profit/ (Loss) Before Tax (V+VI)**	(125.72)	(116.12)	(29.95)	(201.13)
VIII	**Tax Expense**				
	Current Tax	-	-	-	-
	Short / Excess Provision of earlier years	-	-	-	-
	Deferred Tax (Asset) / Liability	(18.22)	(19.75)	(2.75)	(29.15)
IX	**Profit/(Loss) for the period from Continuing Operations (VII-VIII)**	**(107.50)**	**(96.37)**	**(27.20)**	**(171.98)**
	Other Comprehensive Income				
	Items that will not be reclassified subsequently to profit or loss				
	(a) Actuarial gain / (loss)	1.85	9.90	(0.89)	7.40
	Tax Effect thereon	-	-	-	-
	(b) Fair Value change through Other Comprehensive Income	0.96	1.75	(1.08)	0.95
	Tax Effect thereon	(0.14)	(0.25)	(0.21)	(0.50)
X	**Other Comprehensive Income / (Loss) for the period, net of tax**	**2.67**	**11.40**	**(2.18)**	**7.85**
XI	**Total Comprehensive Income after tax (IX + X)**	**(104.83)**	**(84.97)**	**(29.38)**	**(164.13)**
XII	Paid-up equity share capital (Face value of Rs.10/- each)	590.04	590.04	590.04	590.04
XIII	Other Equity				4,853.37
XIV	Earnings per share (of Rs.10/- each) - Not annualised:				
	Basic & Diluted	(1.82)	(1.63)	(0.46)	(2.91)

STAMPED FOR IDENTIFICATION NVC & ASSOCIATES LLP Chartered Accountants

MAKERS LABORATORIES LIMITED

Notes:

1 The above unaudited financial results as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on August 07, 2026.

2 The Statutory Auditors have carried out Limited Review of the aforesaid results and have issued their unmodified report thereon.

3 The above standalone unaudited financial results are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as Amended).

4 The Company has only one reportable segment viz.'Pharmaceuticals' and as such there are no separate reportable segment as per Indian Accounting Standard "Operating Segment (Ind AS-108)"

5 The figures of the quarter ended March 31, 2026 are the balancing figures between the figures for the audited full financial year and year to date unaudited figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors.

6 Figures of the previous period have been regrouped to confirm to the figures of the current period's classification wherever necessary.

MAKERS LABORATORIES LIMITED

By Order of the Board
For Makers Laboratories Limited

Saahil Parikh
Wholetime Director & CEO
(DIN 00400079)

Place : Mumbai,
Date : August 07,2026

STAMPED FOR IDENTIFICATION
N V C & ASSOCIATES LLP
Chartered Accountants
MUMBAI

N V C & Associates LLP
Chartered Accountants
903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email : nvc@nvc.in LLPIN - ACM-9656

Independent Auditor's Review Report on Unaudited Standalone Financial Results of Makers Laboratories Limited for the quarter ended June 30, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as Amended)

To,
The Board of Directors of
Makers Laboratories Limited.

1. We have reviewed the accompanying statement of standalone unaudited financial results ("the Statement") of Makers Laboratories Limited ("the Company") for the quarter ended June 30, 2026, being submitted by the Company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind-AS 34) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion in our report on this statement of unaudited standalone financial results based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

N V C & Associates LLP
Mumbai
Chartered Accountants

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable accounting standards as specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N V C & Associates LLP
Chartered Accountants
Firm Registration Number: 106971W/W101085

Nuzhat Khan
Partner
M. No. 124960
Mumbai Dated: August 07, 2026
UDIN: 26124960HUAKNV2853

Makers Laboratories Limited
Regd. Office : 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067
CIN : L24230MH1984PLC033389
Tel:+91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com

Statement of Unaudited Consolidated Financial Results for quarter ended June 30, 2026

(All Figures are Rupees in Lacs unless otherwise stated)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	4,277.16	3,575.17	3,500.10	14,059.48
II	Other Income	60.93	76.09	26.61	170.96
III	**Total Income (I + II)**	**4,338.09**	**3,651.26**	**3,526.71**	**14,230.44**
IV	**Expenses:**				
	a) Cost of materials consumed	1,502.20	1,098.33	816.19	4,453.55
	b) Purchases of stock-in-trade	546.96	571.84	702.96	2,220.36
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(19.78)	(186.39)	379.57	(116.51)
	d) Employee benefits expense	408.09	391.01	379.15	1,558.58
	e) Finance Cost	14.86	16.94	18.07	77.12
	f) Depreciation and amortisation expense	112.93	113.16	112.20	452.77
	g) Other expenses	1,143.34	1,173.02	920.94	4,469.64
	Total Expenses (IV)	**3,708.60**	**3,177.91**	**3,329.08**	**13,115.51**
V	**Profit/ (Loss) Before exceptional items and Tax (III-IV)**	**629.49**	**473.35**	**197.63**	**1,114.93**
VI	Exceptional Items income/ (expenses)	-	-	-	-
VII	**Profit/ (Loss) Before Tax (V+VI)**	**629.49**	**473.35**	**197.63**	**1,114.93**
VIII	**Tax Expense**				
	Current Tax	199.96	155.67	60.35	353.40
	Short /(Excess) Provision of earlier years	-	(15.17)	10.78	(4.39)
	Deferred Tax (Asset) / Liability	(30.11)	(23.10)	(2.11)	(20.16)
IX	**Net Profit / (Loss) after tax but before non-controlling interests(VII-VIII)**	**459.64**	**355.95**	**128.61**	**786.08**
X	Less: Share of non-controlling interests	(309.21)	(246.60)	(84.94)	(550.95)
XI	**Net Profit / (Loss) after share of non-controlling interests (IX-X)**	**150.43**	**109.35**	**43.67**	**235.13**
XII	**Other Comprehensive Income**				
	(a) Actuarial gain / (loss)	1.90	14.22	(0.73)	3.97
	Tax Effect thereon	(0.01)	(1.12)	(0.04)	0.89
	(b) Fair Value change through Other Comprehensive Income	0.96	1.75	(1.08)	0.95
	Tax Effect thereon	(0.14)	(0.25)	(0.21)	(0.50)
	Other Comprehensive Income / (Loss) for the period, net of tax	**2.71**	**14.60**	**(2.06)**	**5.31**
XIII	**Total Comprehensive Income after tax (IX + XII)**	**462.35**	**370.55**	**126.55**	**791.39**
	Profit/(Loss) for the period attributable to :				
	Owners of the parent	150.43	109.35	43.67	235.13
	Non-controlling interest - profit / (loss)	309.21	246.60	84.94	550.95
		459.64	**355.95**	**128.61**	**786.08**
	Other Comprehensive Income for the period attributable to :				
	Owners of the parent	2.69	12.85	(2.13)	6.69
	Non-controlling interest - profit / (loss)	0.02	1.75	0.07	(1.38)
		2.71	**14.60**	**(2.06)**	**5.31**
	Total Comprehensive Income for the period attributable to :				
	Owners of the parent	153.12	122.20	41.54	241.82
	Non-controlling interest - profit / (loss)	309.23	248.35	85.01	549.57
		462.35	**370.55**	**126.55**	**791.39**
XIV	Paid-up equity share capital (Face value of Rs.10/- each)	590.04	590.04	590.04	590.04
XV	Other Equity				6,702.37
XVI	Earnings per share (of Rs.10/- each) - Not annualised :				
	Basic & Diluted	2.55	1.85	0.74	3.99

STAMPED FOR IDENTIFICATION
N V C & ASSOCIATES LLP
Chartered Accountants

MAKERS LABORATORIES LIMITED

Notes:

1 The above unaudited consolidated financial results as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 07th August, 2026.

2 The Statutory Auditors have carried out Limited Review of the aforesaid results and have issued their unmodified report thereon.

3 The above consolidated financial results are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as Amended).

4 The group has two reportable segments viz. "Pharmaceutical" and " Chemical Manufacturing" as per Indian Accounting Standard "Operating Segment (Ind AS- 108). Segment information is given here in below:

(All Figures are Rupees in Lacs)

Particulars	Quarter Ended			Year Ended
	30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue				
- Pharmaceutical	1,025.90	1,129.92	1,376.58	5,041.51
- Chemical Manufacturing	3,312.19	2,521.34	2,150.13	9,188.93
Segment Results - PBT				
- Pharmaceutical	(125.74)	(116.11)	(29.96)	(253.63)
- Chemical Manufacturing	755.23	589.46	227.57	1,368.56
Total PBT	629.49	473.35	197.61	1,114.93
Tax	(169.85)	(117.40)	(69.02)	(328.85)
Total PAT	**459.64**	**355.95**	**128.59**	**786.08**
Segment Assets				
- Pharmaceutical	5,124.41	5,109.32	5,096.88	5,109.32
- Chemical Manufacturing	11,521.05	11,552.60	9,971.08	11,552.60
Segment Liabilities				
- Pharmaceutical	2,030.26	1,910.32	1,763.14	1,910.32
- Chemical Manufacturing	1,905.19	2,503.96	1,659.09	2,503.96

5 The figures of the quarter ended March 31, 2026 are the balancing figures between the figures for the audited full financial year and year to date unaudited figures up to the third quarter of the respective financial years which were subjected to limited review by the statutory auditors.

6 Figures for the previous period have been regrouped to confirm to the figures of the current period's classification wherever necessary.

By Order of the Board

For Makers Laboratories Limited

MAKERS LABORATORIES LIMITED

Saahil Parikh

Wholetime Director & CEO

(DIN 00400079)

Place : Mumbai,

Date : 07 August , 2026

STAMPED FOR IDENTIFICATION
N V C & ASSOCIATES LLP
Chartered Accountants
MUMBAI

N V C & Associates LLP
Chartered Accountants

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel.: (91-22) 6752 7100 Email : nvc@nvc.in LLPIN - ACM-9656

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of Makers Laboratories Limited for the Quarter ended June 30, 2026, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors of
Makers Laboratories Limited,

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Makers Laboratories Limited (the Parent and its subsidiary together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

N V C & Associates LLP Mumbai Chartered Accountants

5. The Statement includes unaudited standalone financial results of the following entities:

Name of the Entities
Makers Laboratories Limited- Holding Company
Subsidiary
Resonance Specialties Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 and 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the unaudited financial results of the subsidiary whose interim financial results reflects total revenue (including other income) of Rs. 3,312.19 Lakhs and total net profit after tax (including OCI) of Rs. 574.46 Lakhs for the quarter ended June 30, 2026, respectively, as considered in the statement. These financial statements, which have been considered, are reviewed by the respective independent auditor whose report has been furnished to us and our conclusion in the statement, in so far as it relates to the subsidiary is based on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the statement is not modified in respect of this matter.

N V C & Associates LLP
Chartered Accountants
Firm Registration Number: 106971W/W101085

Nuzhat

Nuzhat Khan
Partner
M. No. 124960
Mumbai Dated: August 07, 2026
UDIN: 26124960SCRSRJ9569

N V C & Associates LLP Mumbai Chartered Accountants